(0554–0592) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I

Sunday, October 26, 2025

10:30 AM - 12:30 PM Central Time

Location: Hall F1

CE: 0.00

Presentations:

10:30 AM - 12:30 PM Central Time

An Interim Analysis of Health-related Quality of Life Outcomes from an International Multicentre Observational Study in Patients with Axial Spondyloarthritis Initiating Bimekizumab in Real-world Clinical Practice
Abstract Poster Presenter: Xenofon Baraliakos, MD – Rheumazentrum Ruhrgebiet
10:30 AM - 12:30 PM Central Time

An Interim Analysis of Health-related Quality of Life Outcomes from an International Multicentre Observational Study in Patients with Psoriatic Arthritis Initiating Bimekizumab in Real-world Clinical Practice
Abstract Poster Presenter: Xenofon Baraliakos, MD – Rheumazentrum Ruhrgebiet
10:30 AM - 12:30 PM Central Time

ASAS Recommendations on Reporting Outcomes of Core Outcome Set Instruments in Axial Spondyloarthritis Clinical Trials
Abstract Poster Presenter: Floris van Gaalen, MD – LUMC
10:30 AM - 12:30 PM Central Time

Baseline Peripheral Phenotypes Are Associated with Differential Response to TNF Inhibitors in Psoriatic Arthritis. A Cluster Analysis Approach
Abstract Poster Presenter: Raquel Granados, MD – Hospital Universitario Reina Sofia
10:30 AM - 12:30 PM Central Time

Bimekizumab 3-Year Efficacy In Patients With Psoriasis And Risk Factors For Progression To Psoriatic Arthritis Or Screening Positive For Psoriatic Arthritis: Long-Term Results From Five Phase 3/3b Trials
Abstract Poster Presenter: Joseph Merola, MD, MSc, FACR, FAAD – UT Southwestern Medical Center
10:30 AM - 12:30 PM Central Time

Characteristics and Treatment Patterns among Patients with Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry Initiating a Third or Higher Line of Biologic or Targeted Disease-Modifying Antirheumatic Drug Therapy
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
10:30 AM - 12:30 PM Central Time

Combination of Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Psoriatic Arthritis: A Case-Series
Abstract Poster Presenter: Andre Lucas Ribeiro (he/him/his) – Universidade Federal do Rio Grande do Sul
10:30 AM - 12:30 PM Central Time

Comparing Efficacy of Upadacitinib in Male and Female Patients with axSpA: Results from the SELECT-AXIS 1 and 2 Trials
Abstract Poster Presenter: Sofia Ramiro, MD, PhD – Leiden University Medical Center
10:30 AM - 12:30 PM Central Time

Difficult-to-Manage Axial Spondyloarthritis According to ASAS Criteria in Reuma-Check Cohort: Frequency, Predictive Factors, and Treatment Patterns.
Abstract Poster Presenter: Rodrigo Garcia Salinas, MD – Hospital Italiano La Plata
10:30 AM - 12:30 PM Central Time

Drug-Free Remission in Early Peripheral Spondyloarthritis: 10-year follow-up from the CRESPA-trial
Abstract Poster Presenter: Caroline Damen, MD – UZ Gent
10:30 AM - 12:30 PM Central Time

Early Systemic and Skin Pharmacodynamic Effects of Icotrokinra in Participants with Moderate-to-Severe Plaque Psoriasis: Results Through Week 24 of the Phase 3, ICONIC-LEAD Study
Abstract Poster Presenter: Monica Leung, n/a – Johnson & Johnson, San Diego, CA, USA
10:30 AM - 12:30 PM Central Time

Effect of Deucravacitinib Treatment on Disease Activity–Associated Plasma Biomarkers in Patients With Active Psoriatic Arthritis: Results From 2 Phase 3 Studies
Abstract Poster Presenter: Vinod Chandran, MD, PhD, MBBS, DM, FRCPC – University of Toronto
10:30 AM - 12:30 PM Central Time

Effects of Apremilast on Body Mass Index, Weight, and HbA1c as Cardiometabolic Outcomes in Patients With Early Oligoarticular Psoriatic Arthritis in the FOREMOST Study
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
10:30 AM - 12:30 PM Central Time

Effects of Sonelokimab, an IL-17A- and IL-17F-Inhibiting Nanobody, on Patient-Reported Symptoms and Quality of Life in Psoriatic Arthritis: Results From the Randomized, Double-Blind, Placebo-Controlled Phase 2 ARGO Trial
Abstract Poster Presenter: Joseph Merola, MD, MSc, FACR, FAAD – UT Southwestern Medical Center
10:30 AM - 12:30 PM Central Time

Efficacy and Safety of Guselkumab in Patients with Active Psoriatic Arthritis and Inadequate Response and/or Intolerance to One Prior Tumor Necrosis Factor Inhibitor
Abstract Poster Presenter: Alexis Ogdie, MD – University of Pennsylvania
10:30 AM - 12:30 PM Central Time

Efficacy of Upadacitinib in Male and Female Patients with PsA: Results from the SELECT-PsA 1 and 2 Trials
Abstract Poster Presenter: Lucia Novelli, MD – AbbVie
10:30 AM - 12:30 PM Central Time

Evaluating the Efficacy of Sulfasalazine Compared to Placebo in the Treatment of Psoriatic Arthritis in Adults: A Systematic Review and Meta-Analysis
Abstract Poster Presenter: Khadija Mohib, MD – Kirk Kerkorian School of Medicine at UNLV
10:30 AM - 12:30 PM Central Time

Factors impacting progression from oligoarticular to polyarticular PsA: Data from the FOREMOST study
Abstract Poster Presenter: Laura Coates, MD, PhD – University of Oxford
10:30 AM - 12:30 PM Central Time

Fungal Infections, Including Candida, in Patients With Active Axial Spondyloarthritis Treated With Secukinumab: A Pooled Analysis of 10 Phase 3 Trials
Abstract Poster Presenter: Shikha Singla, MD – MCW
10:30 AM - 12:30 PM Central Time

Icotrokinra (ICO), a Novel Targeted Oral Peptide, in Patients (Pts) With Psoriatic Disease: Exploratory Assessments From a Phase 2 Psoriasis (PsO) Study Informing a Phase 3 Clinical Program in Psoriatic Arthritis (PsA)
Abstract Poster Presenter: Alexis Ogdie, MD – University of Pennsylvania
10:30 AM - 12:30 PM Central Time

Immune Checkpoint agonists: A New horizon for treatment of psoriatic arthritis
Abstract Poster Presenter: Siba Raychaudhuri, MD – UC Davis, School of Medicine/ VA Medical Center, Sacramento
10:30 AM - 12:30 PM Central Time

Impact of Secukinumab on Cardiovascular Disease in Patients with Psoriasis, PsA, and Axial Spondyloarthritis: A Systematic Review of Existing Evidence
Abstract Poster Presenter: Nehal Mehta, MD MSCE – The George Washington University School of Medicine and Health Sciences
10:30 AM - 12:30 PM Central Time

Improvements in Patient Reported Outcomes Through 24 Weeks of Guselkumab Treatment in Participants with Active Psoriatic Arthritis and Inadequate Response and/or Intolerance to One Prior Tumor Necrosis Factor Inhibitor
Abstract Poster Presenter: Alice Gottlieb, MD, PhD – Icahn School of Medicine at Mount Sinai
10:30 AM - 12:30 PM Central Time

Long-Term Efficacy and Safety of Tofacitinib in Active Axial Spondyloarthritis: Experience from a Tertiary Care Center in South India
Abstract Poster Presenter: Prabhu Vasantha Kumar, MD, DM – GKNM Hospitals & Research Institute, Coimbatore, Tamil Nadu, India
10:30 AM - 12:30 PM Central Time

Patient Characteristics and Treatment Patterns of Traditional and Advanced Therapies Prior to First Secukinumab Intravenous (IV) Administration in Patients with Spondyloarthritis (SpA) in US Real-World Clinical Settings
Abstract Poster Presenter: Alan Kivitz, MD, MACR – Altoona Center for Clinical Research
10:30 AM - 12:30 PM Central Time

Persistence and Disease Activity Control among Patients with Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry Initiating a Third or Higher Line of Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drug Therapy
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
10:30 AM - 12:30 PM Central Time

Persistence and Effectiveness Across PsA Patient Subgroups with Guselkumab and IL-17 Inhibitors: 6-Month Results of the PsABIOnd Observational Study
Abstract Poster Presenter: Laure Gossec, MD;PhD – Sorbonne Universite and Pitie-Salpetriere Hospital
10:30 AM - 12:30 PM Central Time

Phase 3 Results From an Innovative Trial Design of Treating Plaque Psoriasis Involving Difficult-to-Treat, High-Impact Sites With Icotrokinra, a Targeted Oral Peptide That Selectively Inhibits the IL-23–Receptor
Abstract Poster Presenter: Joseph Merola, MD, MSc, FACR, FAAD – UT Southwestern Medical Center
10:30 AM - 12:30 PM Central Time

Phyto- and Endo-cannabinoids Exhibit Ex Vivo Anti-Inflammatory Effects in Refractory Rheumatic inflammatory/Autoimmune Patients: Toward Personalized Cannabinoid Therapy
Abstract Poster Presenter: Gilad Halpert, PhD – Reichman University
10:30 AM - 12:30 PM Central Time

Predictor Risk Factors For Developing Difficult-to-Treat Psoriatic Arthritis in Patients Initiating a First bDMARD: a Binational Study
Abstract Poster Presenter: Astrid Goudot, MD – Université de Lille
10:30 AM - 12:30 PM Central Time

Real world experience with generic Tofacitinib in Axial Spondyloarthritis from North India
Abstract Poster Presenter: Akanksha Kapoor, MD, MBBS (she/her/hers) – Bharati Vidyapeeth Medical College
10:30 AM - 12:30 PM Central Time

Real-world Effectiveness of Upadacitinib on Group for Research and Assessment of Psoriasis and Psoriatic Arthritis Core Domains for Patients with Psoriatic Arthritis: Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
10:30 AM - 12:30 PM Central Time

Real-World Treat-to-Target Strategy in Psoriatic Arthritis: 48-week Results from the MONITOR-PsA Cohort
Abstract Poster Presenter: Jean-Guillaume Letarouilly, PhD, MD – CHU Lille
10:30 AM - 12:30 PM Central Time

Regulatory Role of IL17 F in the Pannus Formation of Psoriatic Arthritis: A Comparative Study with IL-17A
Abstract Poster Presenter: Siba Raychaudhuri, MD – UC Davis, School of Medicine/ VA Medical Center, Sacramento
10:30 AM - 12:30 PM Central Time

Single Cell Sequencing Analysis of Tumour Necrosis Factor Inhibitor Drug Response Reveals Enrichment of Pro-inflammatory Pathway in Non-responders and Amino Acid Metabolic Pathways in Responders
Abstract Poster Presenter: Phuong Nguyen, BSc – University of Toronto
10:30 AM - 12:30 PM Central Time

Single-cell RNA Sequencing Highlights the Role of Innate Immunity in Identifying Candidates for Early Biologics Treatment in Axial Spondyloarthritis
Abstract Poster Presenter: Jaejoon Lee, MD;PhD – Samsung Medical Center, Sungkyunkwan University School of Medicine
10:30 AM - 12:30 PM Central Time

Sonelokimab in Biologic-Experienced Patients With Active Psoriatic Arthritis: Results From a Phase 2 Trial (ARGO) and Study Design of a Phase 3 Trial (IZAR-2) in Patients With Inadequate Response or Intolerance to Biologic TNFi, Including a Risankizumab Reference Arm
Abstract Poster Presenter: Atul Deodhar, MD – Oregon Health & Science University
10:30 AM - 12:30 PM Central Time

The effect of biological and targeted synthetic DMARDs on peripheral manifestations in axial spondyloarthritis: a systematic literature review
Abstract Poster Presenter: Sofia Ramiro, MD, PhD – Leiden University Medical Center
10:30 AM - 12:30 PM Central Time

Why Do Some Psoriatic Arthritis Patients Fail Treatment? Exploring the Profile of D2T Patients
Abstract Poster Presenter: Laia de Daniel Bisbe, -None- – Hospital Universitari de Bellvitge